Immunoscore and Immunoprofiling in cancer: An update from the melanoma and immunotherapy bridge 2015

Journal of Translational Medicine

Volumn 14, Issue 1, 2016, Pages

  Galon, J ^a,b   Fox, B A ^c,d   Bifulco, C B ^c   Masucci, G ^e   Rau, T ^f   Botti, G ^g   Marincola, F M ^h   Ciliberto, G ^g   Pages, F ^a,b,i,j   Ascierto, P A ^g   Capone, M ^g  

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF BERN   (Switzerland)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

ⁱ CENTRE DE RECHERCHE DES CORDELIERS   (France)

^j HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

Immunoprofiling; Immunoscore; Melanoma

Indexed keywords

CD45RO ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA A ANTIGEN; HLA G ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; COLORECTAL CANCER; GENE MUTATION; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOSCORE; IMMUNOTHERAPY; MELANOMA; NON SMALL CELL LUNG CANCER; SCORING SYSTEM; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; IMMUNOLOGY;

HUMANS; IMMUNOTHERAPY; MELANOMA;

EID: 84988600706     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-016-1029-z     Document Type: Article

References (24)

1. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-4.
2. Feng Z, Puri S, Moudgil T, et al. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J Immunother Cancer. 2015;3:47.
3. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014;232:199-209.
4. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29:610-8.
5. Pages F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27:5944-51.
6. Anitei M-G, Zeitoun G, Mlecnik B, et al. Prognostic and predictive values of the Immunoscore in patients with rectal cancer. Clin Cancer Res. 2014;20:1891-9.
7. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568-71.
8. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311-9.
9. Koelzer VH, Lugli A, Dawson H, et al. CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival. J Transl Med. 2014;12:81.
10. Fridman WH, Pages F, Sautes-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298-306.
11. Berghoff AS, Fuchs E, Ricken G, et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology. 2016;5:e1057388.
12. Cochran AJ, Morton DL, Stern S, et al. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol. 2001;14(6):604-8.
13. Cochran AJ, Wen DR, Huang RR, et al. Prediction of metastatic melanoma in non sentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol. 2004;17(7):747-55.
14. Mohos A, Sebestyén T, Liszkay G, et al. Immune cell profile of sentinel lymph nodes in patients with malignant melanoma-FOXP3 + cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome. J Transl Med. 2013;11:1-11.
15. Mozzillo N, Caraco C, Marone U, et al. Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors. World J Surg Oncol. 2013;11:36.
16. Capone M, Madonna G, Sebastiao N, et al. Immunoscore: a new possible approach for melanoma classification. J Immunother Cancer. 2014;2:P193.
17. Bifulco C, Capone M, Feng Z, et al. MISIPI study: melanoma ImmunoScore evaluation in patients treated with IPIlimumab. J Transl Med. 2014;12:P11-2.
18. Herbst RS, Soria J-C, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-7.
19. McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2(1):46-54.
20. Mlecnik B, Bindea G, Angell HK, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med. 2014;6(228):228ra37.
21. Mlecnik B, Tosolini M, Charoentong P, et al. Biomolecular network reconstruction identifies T cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010;138(4):1429-40.
22. Bindea G, Mlecnik B, Tosolini M, et al. Spatio-temporal dynamics of intratumoral cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782-95.
23. Mlecnik B, Bindea G, Angell AK, et al. The mechanistic relationship and prognostic prevalence of Immunoscore on DNA-mismatch repair deficiency in colorectal cancer. Immunity. 2016;44(3):698-711.
24. Galon J, Angell HK, Bedognetti D, et al. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity. 2013;39:11-26.